Vixarelimab

韦克瑞利单抗

Report date: 2026/02/25 20:02:36

Base Information

Drug NameVixarelimab
Drug Alias NameKPL-716BIIB-069RG-6536RO-7622888
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionOncostatin-M-specific receptor subunit beta inhibitors
TargetsOncostatin-M-specific receptor subunit beta
Therapy Area/IndicationsPlaque psoriasisPrurigo NodularisChronic Urticaria +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[19] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesKiniksa Pharmaceuticals LtdGenentech Inc
Inactive CompaniesRoche (China) Holding Ltd
Active IndicationsPrurigo NodularisPruritusColitis, Ulcerative
Inactive IndicationsPlaque psoriasisChronic UrticariaLichen Planus +[4] 

Other Information

ATC CodeN/A
Related LinksN/A